neo-8k_20170725.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549 

 

FORM 8-K 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

July 25, 2017

 

NEOGENOMICS, INC.

(Exact name of registrant as specified in its charter) 

 

 

 

 

 

 

 

 

 

 

 

 

Nevada

 

001-35756

 

74-2897368

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

 

 

 

 

 

 

12701 Commonwealth Drive, Suite 9, Fort Myers, Florida

 

33913

(Address of principal executive offices)

 

(Zip Code)

(239) 768-0600

(Registrant’s telephone number, including area code) 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 


 

 

 

 

 

 

Item 2.02.

Results of Operations and Financial Condition.

On July 25, 2017, NeoGenomics, Inc. (the “Company”) issued a press release reporting its results for its second fiscal quarter of 2017.  The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

 

 

 

 

 

Item 9.01.

Financial Statements and Exhibits.

 

 

 

 

 

(a)

Not applicable

 

 

 

 

 

(b)

Not applicable

 

 

 

 

 

(c)

Not applicable

 

 

 

 

 

(d)

Exhibits.

 

 

 

 

 

99.1

Press Release of NeoGenomics, Inc. dated July 25, 2017.

 

 

 


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

NEOGENOMICS, INC.

 

 

By:

 

/s/ George Cardoza

 

 

George Cardoza

 

 

Chief Financial Officer

Date: July 25, 2017

 

 

 


 

 

 

Exhibit Index

 

 

 

 

 

 

 

Exhibit
No.

  

Description

 

 

99.1

  

Press Release of NeoGenomics, Inc. dated July 25, 2017.